11C-metomidate PET imaging of adrenocortical cancer

@article{Khan200211CmetomidatePI,
  title={11C-metomidate PET imaging of adrenocortical cancer},
  author={T. Khan and A. Sundin and C. Juhlin and B. L{\aa}ngstr{\"o}m and M. Bergstr{\"o}m and B. Eriksson},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2002},
  volume={30},
  pages={403-410}
}
Abstract. The diagnostic potential of positron emission tomography (PET) with carbon-11 metomidate in patients with adrenocortical cancer (ACC) was evaluated. Thirteen PET examinations were performed in 11 patients with CT-detected primary tumours or recurrence and/or metastases from a previously histopathologically proven ACC. The findings at PET were compared with those at CT and verified by histopathology. Six studies (group A) were performed in patients who at the time of imaging were free… Expand
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings.
TLDR
MTO-PET is useful in the imaging work-up of adrenal incidentalomas and may be beneficial for the examination of patients with primary aldosteronism or ACC. Expand
Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
TLDR
Abnormal FDG uptake correctly indicated tumor recurrence in 10 patients and one patient with no abnormal FDG activity had a morphological abnormality subsequently proven to be a postoperative scar. Expand
Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate
Purpose11C-metomidate (MTO), a marker of 11β-hydroxylase, has been suggested as a novel positron emission tomography (PET) tracer for adrenocortical imaging. Up to now, experience with this very newExpand
Imaging of Adrenal Masses with Emphasis on Adrenocortical Tumors
TLDR
In oncological patients, especially when the morphological imaging criteria indicate an adrenal metastasis, biopsy of the lesion should be considered after pheochromocytoma is ruled out biochemically, and functional imaging mainly by positron emission tomography (PET) is available using various tracers. Expand
FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma
TLDR
18F-fluorodeoxyglucose positron emission tomography (FDG PET) is routinely used for other malignancies and, on the basis of published data, is also becoming a promising tool in the management of ACC. Expand
Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas.
TLDR
The diagnosis of an adrenocortical adenoma may be established by CT in most patients and by MRI in an additional number of patients for the few remaining patients needing further characterisation, MTO-PET is advantageous as an additional imaging modality. Expand
Positron emission tomography (PET) in endocrine tumours
TLDR
The role of FDG PET in phaeochromocytomas, carcinoids and endocrine pancreatic tumours is probably limited to those that are less well differentiated and metabolically active, however, a future role for PET imaging in the detection of endocrine tumours, using more specific substrates, appears very promising. Expand
Adrenocortical Positron Emission Tomography/PET-CT Imaging.
TLDR
Various PET radiopharmaceutics which can be used for adrenocortical imaging are discussed in detail. Expand
[¹²³I]Iodometomidate imaging in adrenocortical carcinoma.
TLDR
About one-third of patients with ACC show specific retention of [¹²³I]IMTO in metastatic lesions, providing support for the conduct of a prospective trial to determine whether the first molecular informed therapy using[¹³¹I]-IMTO will be of value to patients with metastatic ACC. Expand
[Positron emission tomography in neuroendocrine tumours].
TLDR
Problems associated with use of deoxyfluoroglucose Positron Emission Tomography (PET) and other available options in patients with neuroendocrine tumours are discussed, as well as challenges related to introduction of new radiopharmaceutical agents. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
FDG-PET in adrenocortical carcinoma.
TLDR
FDG-PET is highly useful in ACC and should be included in the work-up for initial staging as well as for follow-up, modifying the subsequent therapeutic management in 2/10 patients. Expand
PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.
TLDR
PET with 11C-metomidate has the potential to be an attractive method for the characterization of Adrenal masses with the ability to discriminate lesions of adrenal cortical origin from noncortical lesions. Expand
Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
TLDR
Evaluating the ability of positron emission tomography to characterize adrenal masses in patients with cancer found PET helped correct differentiation of benign from malignant adrenal lesions in all patients. Expand
Incidentally discovered adrenal tumors: an institutional perspective.
TLDR
Analysis of computerized tomographic scans of 2066 patients with adrenal masses from 1985 through 1989 suggests biochemical screening in patients with incidentalomas larger than 1 cm, surgical excision of tumors 4 cm or greater, and a comparison CT scan approximately 3 months after diagnosis in Patients with tumors less than 4 cm in whom observation has been chosen. Expand
Scintigraphic evaluation of clinically silent adrenal masses.
TLDR
These data confirm earlier observations that the functional information depicted by scintigraphy complements the morphological evaluation by CT and in the absence of hormonal dysfunction, the presence of concordant CT and 131I-NP-59 scans are characteristic of functioning, but not hypersecretory, benign adrenocortical adenomas. Expand
Clinical application of SPECT in adrenal imaging with iodine-131 6 beta-iodomethyl-19-norcholesterol.
TLDR
The data show that it is possible to evaluate the adrenocortical functioning status simply by analyzing the SPECT images of the adrenal, and all glands with either normally functioning or hyperfunctioning adrenal cortices could be detected, while those glands with hypofunctioning adrenals could not be detected. Expand
Iodocholesterol adrenal tissue uptake and imaging adrenal neoplasms.
TLDR
A quantitative assessment of the differences in radioactivity concentration required for imaging of adrenal tumors is provided and it is demonstrated that differences in the concentration of radioactivity within adrenal carcinomas and adenomas corresponds to their ability to release cortisol in vitro. Expand
Incidental asymptomatic adrenal masses detected by computed tomographic scanning. Is operation required?
TLDR
With wider application of CT imaging, increasing numbers of asymptomatic adrenal masses will be detected and care in interpreting the clinical significance of these masses and caution in recommending treatment are required. Expand
Imaging the adrenal glands with radiolabeled inhibitors of enzymes: concise communication.
TLDR
The relative tissue distributions of two radiolabeled enzyme inhibitors [3H] metyrapol and I-125-SKF-12185 were studied in dogs and man and it would be desirable to decrease the time for imaging and decrease the radiation dose. Expand
Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging.
TLDR
The high reproducibility of NP-59 scintigraphic interpretation was demonstrated when 40 random cases underwent interinstitutional exchange and through interobserver evaluation at the University of Michigan, and Responses of 85/126 medical centers to questionnaires revealed the high level ofNP-59 safety. Expand
...
1
2
...